Acetylator Phenotype in Patients with Hydralazine‐induced Lupoid Syndrome
Authors:
- 12 January 1976
- journal article
- research article
- Published by Wiley in Acta Medica Scandinavica
- Vol. 200 (1-6) , 367-371
Abstract
The acetylator phenotype has been determined (isoniazid half‐life) in 31 patients, 25 of them women, who had exhibited a lupus erythematosus‐like syndrome during treatment with hydralazine. Twenty‐nine patients were slow acetylators, one was rapid (probably spontaneous SLE) and one uncertain. Only two patients had been given more than 200 mg of hydralazine daily. The mean duration of therapy was 32 months at the onset of symptoms. These were not serious but rather long‐standing. Our study confirms that patients who risk developing hydralazine lupus are slow acetylators, especially females, treated with more than 100 mg daily. Rapid acetylators seem to develop this side‐effect rarely, if at all.Keywords
This publication has 22 references indexed in Scilit:
- Spontaneous Systemic Lupus Erythematosus and Acetylator PhenotypeActa Medica Scandinavica, 1977
- Antinuclear antibodies during procainamide treatment and drug acetylation.BMJ, 1975
- POLYMORPHIC ACETYLATION OF PROCAINE AMIDE IN HEALTHY SUBJECTSActa Medica Scandinavica, 1975
- Effects of Long‐term Treatment with Procaine AmideActa Medica Scandinavica, 1975
- Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritisThe American Journal of Medicine, 1973
- Criteria for the classification of systemic lupus erythematosus—status 1972Arthritis & Rheumatism, 1972
- Antinuclear factor in rapid and slow acetylator patients treated with isoniazid.Journal of Medical Genetics, 1972
- Isoniazid acetylatlon rate and development of antinuclear antibodies upon isoniazid treatmentArthritis & Rheumatism, 1971
- CLINICAL AND EXPERIMENTAL STUDIES ON THE HYDRALAZINE SYNDROME AND ITS RELATIONSHIP TO SYSTEMIC LUPUS ERYTHEMATOSUSMedicine, 1967
- Genetic Control of Isoniazid Metabolism in ManBMJ, 1960